The GLP-1 Effect: How Weight-Loss Drugs Are Changing the Business of Healthcare

America's GLP-1 boom is reshaping healthcare. SHARx co-founder Paul Pruitt explains who pays, why costs are surging, and what comes next.

Jun 8, 2026, 06:51 PM

More Videos

How to Build a Career That Survives the AI Revolution

As AI reshapes the workforce, author Benjamin Todd explains how graduates can build resilient, fulfilling careers and thrive in a changing job market.

Experian's AI Strategy Is Reshaping Financial Services

From Money 20/20, Experian UK & Ireland CEO Malin Holmberg discusses the trends, opportunities and innovations shaping fintech's future.

How The Brooklyn Army Terminal Became NYC's $100 Million Climate Hub

NYC just invested $100 million to turn a historic military base into a climate tech proving ground. We went inside the Brooklyn Army Terminal to find out why.

Why AI Companies May Soon Be Sharing Their Most Powerful Models With the Government

Politico's Cheyenne Haslett breaks down Trump's new AI executive order, the AI race with China, industry reaction, and what's next for regulation.

Inside the Aerospace IPO Positioning for the Next Decade of Defense Growth

Applied Aerospace & Defense CEO Trip Ferguson discusses the company's IPO, defense spending, space innovation, and the future of U.S. aerospace manufacturing.

How Crunch Fitness Is Redefining Your Exercise Routine

Jim Rowley, CEO of Crunch Fitness, discusses affordable fitness, industry growth, and why value-focused gyms continue to attract members.

Who Decides? Who Profits? Who Pays? Inside Trump's D.C. Projects

David Fahrenthold, investigative reporter for The New York Times, examines rising costs, contracts, and transparency concerns in Trump's D.C. projects.